TY - JOUR
T1 - Sodium/glucose co-transporter 1 expression increases in human diseased prostate
AU - Blessing, Alicia
AU - Xu, Lei
AU - Gao, Guang
AU - Bollu, Lakshmi Reddy
AU - Ren, Jiangong
AU - Li, Hangwen
AU - Wu, Xuefeng
AU - Su, Fei
AU - Huang, Wei Chien
AU - Hung, Mienchie
AU - Huo, Lei
AU - Palapattu, Ganesh S.
AU - Weihua, Zhang
PY - 2012
Y1 - 2012
N2 - Sodium/glucose co-transporter 1 (SGLT1) is an active glucose transporter that takes up glucose into cells independent of the extracellular concentration of glucose. This transporter plays a critical role in maintaining glucose homeostasis at both physiological and pathological levels. The expression level of SGLT1 in normal and diseased human prostatic tissue has not been determined. We produced two rabbit polyclonal antibodies against human SGLT1, one each for immunohistochemical and Western blot analyses, and characterized the expression of SGLT1 in human prostate tissues: normal prostate (n=3), benign prostatic hyperplasia (BPH) (n=53), prostatic intraepithelial neoplasia (PIN) (n=9), and prostate cancer (PCa) (n=44). In normal prostate tissue, SGLT1 was weakly expressed exclusively in the epithelium. The transporter was significantly increased in the basal cells and stromal cells of BPH, increased in the epithelial cells of PIN, and frequently overexpressed in stromal cells and universally overexpressed in the tumor cells of PCa. The pattern of expression was shown as membranous/ cytoplasmic staining in low-grade cancer cells and nuclear envelope staining in high-grade cancer cells. The SGLT1-positive stromal cells of BPH and PCa tissues were negative for tenascin, a marker of reactive stromal cells. We concluded that SGLT1 is up-regulated in BPH and PCa, and SGLT1 may serve as a potential therapeutic target for treating these prostate disorders.
AB - Sodium/glucose co-transporter 1 (SGLT1) is an active glucose transporter that takes up glucose into cells independent of the extracellular concentration of glucose. This transporter plays a critical role in maintaining glucose homeostasis at both physiological and pathological levels. The expression level of SGLT1 in normal and diseased human prostatic tissue has not been determined. We produced two rabbit polyclonal antibodies against human SGLT1, one each for immunohistochemical and Western blot analyses, and characterized the expression of SGLT1 in human prostate tissues: normal prostate (n=3), benign prostatic hyperplasia (BPH) (n=53), prostatic intraepithelial neoplasia (PIN) (n=9), and prostate cancer (PCa) (n=44). In normal prostate tissue, SGLT1 was weakly expressed exclusively in the epithelium. The transporter was significantly increased in the basal cells and stromal cells of BPH, increased in the epithelial cells of PIN, and frequently overexpressed in stromal cells and universally overexpressed in the tumor cells of PCa. The pattern of expression was shown as membranous/ cytoplasmic staining in low-grade cancer cells and nuclear envelope staining in high-grade cancer cells. The SGLT1-positive stromal cells of BPH and PCa tissues were negative for tenascin, a marker of reactive stromal cells. We concluded that SGLT1 is up-regulated in BPH and PCa, and SGLT1 may serve as a potential therapeutic target for treating these prostate disorders.
KW - Benign prostatic hyperplasia
KW - Prostate
KW - Prostate cancer
KW - SGLT1
UR - http://www.scopus.com/inward/record.url?scp=84867542076&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84867542076&partnerID=8YFLogxK
U2 - 10.4172/1948-5956.1000159
DO - 10.4172/1948-5956.1000159
M3 - Article
AN - SCOPUS:84867542076
SN - 1948-5956
VL - 4
SP - 306
EP - 312
JO - Journal of Cancer Science and Therapy
JF - Journal of Cancer Science and Therapy
IS - 9
ER -